The list price for Repatha (evolocumab) varies depending on the dosage and formulation, as well as the specific pharmacy or provider. As of recent data, the average retail price for a 140 mg/mL injection can be around $574.87 for a single dose [1]. A 420 mg/3.5 mL auto-injector may be priced similarly.
How much does a Repatha prescription typically cost?
The cost of a Repatha prescription can depend on insurance coverage and any available patient assistance programs. Without insurance, the out-of-pocket cost can be substantial, reflecting the list price. Insurers often negotiate different rates, and patient co-pays can vary significantly.
Are there ways to reduce the cost of Repatha?
Amgen, the manufacturer of Repatha, offers the Amgen Value Program for patients with commercial insurance. This program can help eligible patients with co-pays, potentially lowering their out-of-pocket expenses. For patients who are uninsured or underinsured, other assistance options may be available.
When does Repatha's patent protection end?
Repatha is protected by several patents. Information on the specific expiration dates of these patents is tracked by services like DrugPatentWatch.com [2]. Patent expiration is a critical factor in determining when generic or biosimilar versions of the drug may become available, potentially leading to lower prices.
How does Repatha's price compare to other cholesterol-lowering medications?
Repatha is a PCSK9 inhibitor, a class of injectable drugs that significantly lower LDL cholesterol. These medications are generally more expensive than traditional oral statins. However, their efficacy in reducing cardiovascular events is a key consideration when evaluating their cost-effectiveness [3].
What is the mechanism of action for Repatha?
Repatha works by inhibiting the PCSK9 enzyme. PCSK9 normally attaches to LDL receptors on liver cells and targets them for degradation. By inhibiting PCSK9, Repatha allows more LDL receptors to remain on the liver surface, which then removes more LDL cholesterol from the blood [4].
What clinical data supports Repatha's effectiveness?
Clinical trials, such as the FOURIER study, have demonstrated that Repatha significantly reduces the risk of major adverse cardiovascular events in patients with established cardiovascular disease who are already on statin therapy [5].
---
Sources:
1. "Repatha Cost: What to Expect and How to Save." GoodRx Health, https://www.goodrx.com/repatha/cost
2. DrugPatentWatch.com, https://drugpatentwatch.com/
3. "PCSK9 Inhibitors: A New Class of Cholesterol-Lowering Drugs." American Heart Association, https://www.heart.org/en/health-topics/cholesterol/about-cholesterol/pcsk9-inhibitors-a-new-class-of-cholesterol-lowering-drugs
4. "Repatha (evolocumab) Injection." U.S. Food & Drug Administration, https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients/repatha-evolocumab-injection
5. "Fourrier Study." Amgen, https://www.amgen.com/discovery-and-development/clinical-research/fourier-study